Related Experiment Video
Updated: Sep 26, 2026

09:14
An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay
Published on: January 26, 2019
Effectiveness of nirsevimab reimmunization against RSV hospitalization during the second season in high-risk children
Susana Monge1,2, Olivier Núñez1,3, Roberto Pastor-Barriuso1,3
1National Center for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Journal of the Pediatric Infectious Diseases Society
|September 24, 2026
Abstract:
Results suggest a moderate effectiveness of reimmunization with a second nirsevimab dose against hospitalization for respiratory syncytial virus infection during the second season in high-risk children, although the estimated effectiveness was highly uncertain (42%; 95% confidence interval: -25% to 73%).
More Related Videos
Related Concept Videos
Respiratory Syncytial Virus Disease
Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...
Vaccinations
Overview
Poliomyelitis
Poliomyelitis is caused by poliovirus, a small, non-enveloped, positive-sense RNA virus of the Picornaviridae family and Enterovirus genus. Transmission occurs primarily via the fecal-oral route, often through ingestion of contaminated water or food. The virus initially replicates in the oropharynx and intestinal mucosa, particularly in lymphoid tissues such as the tonsils, Peyer’s patches, and regional lymph nodes. Primary viremia follows, allowing dissemination throughout the body.In most...

